Research programme: acute coronary syndrome therapeutics - MedImmune
Latest Information Update: 14 Oct 2014
At a glance
- Originator Shionogi
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Acute coronary syndromes
Most Recent Events
- 08 Oct 2014 Preclinical trials in Acute coronary syndromes in Japan (unspecified route)